ArticleTrials2021

Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales ("MERINO-3"): study protocol for a multicentre, open-label randomised non-inferiority trial.

Adam G Stewart et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.